Novo Nordisk study finds 6% lower cardiovascular risk with higher-dose semaglutide
AI Summary- Novo Nordisk reported cardiovascular findings comparing higher-dose semaglutide with Eli Lilly’s tirzepatide.
- 636,525 adults were evaluated, with 2 mg semaglutide linked to 6% lower MACE risk.
- Novo secured HRS-1596 rights outside four Chinese markets in an agreement worth up to $2.6 billion.